粒体自噬
帕金
品脱1
线粒体
功能(生物学)
杨梅素
医学
化学
细胞生物学
生物
自噬
遗传学
内科学
生物化学
帕金森病
抗氧化剂
细胞凋亡
山奈酚
疾病
槲皮素
作者
WEILONG XU,Jiangyi Yu,X J Zhou
出处
期刊:Diabetes
[American Diabetes Association]
日期:2025-06-13
卷期号:74 (Supplement_1)
摘要
Introduction and Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD), particularly its severe form, metabolic dysfunction-associated steatohepatitis (MASH), poses a major global health challenge. While traditional Chinese medicine shows promise in MASLD treatment, the mechanisms and efficacy of myricetin, extracted from Abelmoschus manihot (L.) Medic, remain unclear. This study investigates myricetin's effects on liver steatosis, mitochondrial function, and mitophagy in MASLD models, hypothesizing it acts as a therapeutic agent by enhancing mitochondrial function and promoting PINK1/Parkin-dependent mitophagy. Methods: HFD and CD-HFD diets were used to establish mouse models, with hepatic steatosis, inflammation, and systemic insulin resistance evaluated through comprehensive biochemical and histological analyses. RNA sequencing (RNA-seq) was performed to explore the underlying molecular mechanisms, emphasizing fatty acid oxidation and mitophagy pathways. Mitochondrial function and the extent of mitophagy were assessed using TEM, JC-1 staining, and Seahorse metabolic analysis. Results: Myricetin treatment significantly reduced hepatic triglyceride accumulation, decreased serum AST and ALT levels, and improved insulin sensitivity in mice which fed by HFD and CD-HFD diets. RNA-seq analysis revealed an upregulation of genes associated with fatty acid β-oxidation and mitochondrial function. Furthermore, myricetin enhanced mitophagy, as indicated by increased PINK1 and Parkin protein levels and elevated expression of key mitophagy markers. Conclusion: Myricetin alleviates MASLD by enhancing fatty acid β-oxidation and mitochondrial function, presenting a promising therapeutic strategy for MASH. Its promotion of PINK1/Parkin-dependent mitophagy underscores its protective effects on hepatic cells, highlighting broader potential in metabolic disease treatment. Disclosure W. Xu: None. J. Yu: None. X. Zhou: None. Funding National Natural Science Foundation of China (82205025)
科研通智能强力驱动
Strongly Powered by AbleSci AI